52289-55-1

Usage

Uses

Used in Fragrance Industry:
4-Methoxy-2-methylbenzyl alcohol is used as a fragrance ingredient for its distinctive floral and sweet scent. It is incorporated into a wide range of cosmetic and personal care products, such as perfumes, lotions, and soaps, to provide a pleasant and enduring aroma.
Used in Flavor Industry:
In the flavor industry, 4-Methoxy-2-methylbenzyl alcohol serves as a flavoring agent in food and beverages. Its unique scent and taste profile contribute to enhancing the sensory experience of various consumable products.
Used in Pharmaceutical Industry:
4-Methoxy-2-methylbenzyl alcohol is used as an ingredient in pharmaceutical formulations due to its antifungal and antibacterial properties. These characteristics make it a valuable component in the development of treatments and medications that require antimicrobial action.
Used in Disinfectant Products:
Leveraging its antifungal and antibacterial properties, 4-Methoxy-2-methylbenzyl alcohol is also utilized in the production of disinfectant products. Its inclusion helps to ensure cleanliness and hygiene by eliminating harmful microorganisms in various settings.

Upstream product

• 84658-09-3 4-methoxy-2-methylbenzyl chloride 
• 64-19-7 acetic acid 
• 35598-05-1 methyl 4-methoxy-2-methylbenzoate 
• 4685-47-6 3,4-dimethylanisole 
• 133826-75-2 acetic acid 4-methoxy-2-methyl-benzyl ester 
• 100-84-5 1-methoxy-3-methyl-benzene 
• 1028202-57-4 5-methoxy-1,3-dihydroisobenzofuran 
• 578-39-2 4-hydroxy-2-methylbenzoic acid 
• 57556-31-7 4-hydroxy-2-methylbenzoic acid methyl ester 
• 52289-54-0 4-methoxysalicylaldehyde 
• 6245-57-4 4-methoxy-2-methylbenzoic acid 

Downstream Products

• 6245-57-4 4-methoxy-2-methylbenzoic acid 
• 52289-54-0 4-methoxysalicylaldehyde 
• 84658-09-3 4-methoxy-2-methylbenzyl chloride 
• 935740-88-8 4-methoxy-2-[(trimethylsilyl)methyl]benzyl alcohol 
• 935740-89-9 [4-methoxy-2-{(trimethylsilyl)methyl}phenyl]methyl methyl carbonate 
• 65844-56-6 methyl 1,2,3,4-tetrahydro-7-methoxy-2-naphthalenecarboxylate 
• 133826-75-2 acetic acid 4-methoxy-2-methyl-benzyl ester 
• 5456-94-0 2,4-dibromo-5-methylanisole 
• 27060-75-9 4-bromo-3-methylanisole 

Relevant academic research and scientific papers

On the Necessity of Nucleobase Protection for 2-Thiouracil for Fmoc-Based Pseudo-Complementary Peptide Nucleic Acid Oligomer Synthesis

A selection of benzyl-based protecting groups for thiouracil (SU) for the synthesis of pseudo-complementary peptide nucleic acid (PNA) has been evaluated. The 4-methoxybenzyl-protecting group that has found use for SU during Boc-based oligomerization is also suitable for Fmoc-based oligomerization. Furthermore, it is demonstrated that SU protection is unnecessary for the successful synthesis of thiouracil-containing PNA. The new 2-thiothymine (ST) PNA monomer has also been prepared and incorporated into an oligomer and its binding to complementary PNA evaluated.

Design, synthesis, and structure–activity relationship study of potent mapk11 inhibitors

Huntington’s disease (HD) is a rare single-gene neurodegenerative disease, which can only be treated symptomatically. Currently, there are no approved drugs for HD on the market. Studies have found that MAPK11 can serve as a potential therapeutic target f

Incorporation of Pseudo-complementary Bases 2,6-Diaminopurine and 2-Thiouracil into Serinol Nucleic Acid (SNA) to Promote SNA/RNA Hybridization

Serinol nucleic acid (SNA) is a promising candidate for nucleic acid-based molecular probes and drugs due to its high affinity for RNA. Our previous work revealed that incorporation of 2,6-diaminpurine (D), which can form three hydrogen bonds with uracil, into SNA increases the melting temperature of SNA-RNA duplexes. However, D incorporation into short self-complementary regions of SNA promoted self-dimerization and hindered hybridization with RNA. Here we synthesized a SNA monomer of 2-thiouracil (sU), which was expected to inhibit base pairing with D by steric hindrance between sulfur and the amino group. To prepare the SNA containing D and sU in high yield, we customized the protecting groups on D and sU monomers that can be readily deprotected under acidic conditions. Incorporation of D and sU into SNA facilitated stable duplex formation with target RNA by suppressing the self-hybridization of SNA and increasing the stability of the heteroduplex of SNA and its complementary RNA. Our results have important implications for the development of SNA-based probes and nucleic acid drugs.

COMPOUNDS FOR MODULATING DDAH AND ADMA LEVELS, AS WELL AS METHODS OF USING THEREOF TO TREAT DISEASE

Disclosed are compounds that can modulate DDAH and the amount of asymmetric dimethylarginine (ADMA) in a subject. Also provided are pharmaceutical compositions comprising these compounds, as well as methods of using these compositions to treat and/or prevent diseases associated with elevated or low levels of DDAH and ADMA.

PNA monomers fully compatible with standard Fmoc-based solid-phase synthesis of pseudocomplementary PNA

Here we report the synthesis of new PNA monomers for pseudocomplementary PNA (pcPNA) that are fully compatible with standard Fmoc chemistry. The thiocarbonyl group of the 2-thiouracil (sU) monomer was protected with the 4-methoxy-2-methybenzyl group (MMPM), while the exocyclic amino groups of diaminopurine (D) were protected with Boc groups. The newly synthesized monomers were incorporated into a 10-mer PNA oligomer using standard Fmoc chemistry for solid-phase synthesis. Oligomerization proceeded smoothly and the HPLC and MALDI-TOF MS analyses indicated that there was no remaining MMPM on the sU nucleobase. The new PNA monomers reported here would facilitate a wide range of applications, such as antigene PNAs and DNA nanotechnologies.

NOVEL SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND THEIR USE

The invention relates to activators of soluble guanylate cyclase of formula (I) and their use in pharmaceutical compositions, primarily topically administered ophthalmic compositions. The pharmaceutical compositions are useful for reducing intraocular pre

Oxidative hydroxylation mediated by alkoxysulfonium ions

Oxidative hydroxylation of toluene derivatives via alkoxysulfonium ion intermediates was achieved by integration of anodic oxidation and hydrolysis to give benzyl alcohols which are also susceptible to oxidation. Alkenes were also oxidized to give 1,2-diols without overoxidation. The integration of electrochemical oxidative cyclization and hydrolysis was achieved using alkenes bearing a nitrogen atom in an appropriate position to give cyclic β-amino-substituted alcohols.

ESTROGEN RECEPTOR MODULATORS AND USES THEREOF

Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

TETRAHYDROISOQUINOLINE COMPOUND

The present invention relates a specific tetrahydroisoquinoline compound which is useful as a chemokine receptor type 3 (CCR3) antagonist, and a pharmaceutical composition comprising the same as an active ingredient. The tetrahydroisoquinoline compound of the present invention is useful for the treatment or prevention of a disease in which CCR3 participates.

Regioselective reductive opening of substituted phthalans: synthetic applications

The reductive opening of substituted phthalans 6, 11, 12, 20, 21 and 28 with lithium and a catalytic amount of DTBB leads to the formation of corresponding functionalised organolithium intermediates 8, 15, 16, 23, 25 and 29+30 in a regioselective manner. The further reaction of these dianions with different electrophiles, mainly carbonyl compounds, gives the expected functionalised benzylic alcohols 9, 17, 18, 24, 26 and 31+32. The observed stereochemistry can be easily explained taking into account the values of the electron densities deduced by semiempirical PM3 calculations.